NASDAQ:KLRA Kailera Therapeutics (KLRA) Stock Price, News & Analysis $12.70 -0.75 (-5.58%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Kailera Therapeutics Stock (NASDAQ:KLRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kailera Therapeutics alerts:Sign Up Key Stats Today's Range$12.47▼$13.6850-Day Range$12.70▼$21.0152-Week Range$12.47▼$28.23Volume1.13 million shsAverage Volume736,700 shsMarket Capitalization$1.65 billionP/E RatioN/ADividend YieldN/APrice Target$42.75Consensus RatingModerate Buy Company Overview Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders. Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use. The company’s operations are centered on the development of therapies for global markets. Publicly available information about Kailera Therapeutics’ broader pipeline, geographic operations and leadership team is limited.AI Generated. May Contain Errors. Read More Kailera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreKLRA MarketRank™: Kailera Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 333rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingKailera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialKailera Therapeutics has a consensus price target of $42.75, representing about 236.6% upside from its current price of $12.70.Amount of Analyst CoverageKailera Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Kailera Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kailera Therapeutics are expected to decrease in the coming year, from ($3.89) to ($4.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kailera Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kailera Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.37% of the float of Kailera Therapeutics has been sold short.Short Interest Ratio / Days to CoverKailera Therapeutics has a short interest ratio ("days to cover") of 6.46.Change versus previous monthShort interest in Kailera Therapeutics has recently decreased by 6.66%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKailera Therapeutics does not currently pay a dividend.Dividend GrowthKailera Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.24 News SentimentKailera Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Kailera Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for KLRA on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Kailera Therapeutics to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kailera Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsKailera Therapeutics has minimal institutional ownership at this time.Read more about Kailera Therapeutics' insider trading history. Receive KLRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kailera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KLRA Stock News HeadlinesKailera Therapeutics to Participate in Upcoming Investor ConferencesSeptember 16 at 7:10 AM | quiverquant.comQKailera Therapeutics to Participate in September Investor ConferencesSeptember 16 at 7:00 AM | globenewswire.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 16 at 1:00 AM | Behind the Markets (Ad)Kailera Therapeutics Consensus Price Target Decreased by 10.48% to $47.94September 16 at 3:03 AM | msn.comJim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”September 14 at 12:51 AM | insidermonkey.comKailera Therapeutics, Inc. (NASDAQ:KLRA) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 14 at 4:15 AM | americanbankingnews.comKailera Therapeutics (NASDAQ:KLRA) Reaches New 52-Week Low - Should You Sell?September 12, 2026 | americanbankingnews.comKailera Therapeutics Stock Price HistoryAugust 26, 2026 | investing.comSee More Headlines KLRA Stock Analysis - Frequently Asked Questions How have KLRA shares performed this year? Kailera Therapeutics' stock was trading at $26.00 on April 17, 2026. Since then, KLRA stock has decreased by 51.2% and is now trading at $12.70. How were Kailera Therapeutics' earnings last quarter? Kailera Therapeutics, Inc. (NASDAQ:KLRA) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.35. When did Kailera Therapeutics IPO? Kailera Therapeutics (KLRA) raised $586 million in an initial public offering (IPO) on Friday, April 17th 2026. The company issued 39,062,500 shares at $14.00-$16.00 per share. When does Kailera Therapeutics' lock-up period expire? Kailera Therapeutics's lock-up period expires on Wednesday, October 14th. Kailera Therapeutics had issued 39,062,500 shares in its public offering on April 17th. The total size of the offering was $625,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period. Who are Kailera Therapeutics' major shareholders? Top institutional shareholders of Kailera Therapeutics include Atlas Venture Life Science Advisors LLC (3.99%), Wellington Management Group LLP (2.25%), Frazier Life Sciences Management L.P. (0.85%) and Squarepoint Ops LLC (0.03%). Insiders that own company stock include Andrew T Kaplan, Adam Koppel and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Kailera Therapeutics? Shares of KLRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/12/2026Today9/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KLRA CIK2096997 Webwww.kailera.com Phone(508) 440-9475FaxN/AEmployees145Year Founded2024Price Target and Rating Average Price Target for Kailera Therapeutics$42.75 High Price Target$57.00 Low Price Target$30.00 Potential Upside/Downside+236.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio11.11 Quick Ratio11.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares129,640,000Free FloatN/AMarket Cap$1.65 billion OptionableN/A BetaN/A Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:KLRA) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredAfter KDA, PRE, and OCEAN—this is the oneI’ve spent years searching for overlooked cryptos before the crowd catches on. Here are a few of our past reco...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kailera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kailera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
